Learn More
PURPOSE This open-label, randomized, multicenter phase III study compared oral topotecan/intravenous cisplatin (TC) with intravenous (IV) etoposide/cisplatin (PE) in patients with untreated(More)
9721 Background:Tumour response is the major surrogate by which new cancer therapies are evaluated. However, demonstrating a consistent relationship between response and survival has been(More)
7046 Background: IV topotecan is an established therapy in relapsed, "sensitive" SCLC. Oral and IV topotecan have similar activity and tolerability. Phase II data in combination with cisplatin as(More)
  • 1